

Description of Additional Supplementary Files

File Name: Supplementary Data 1

Description: Annotated compounds and count values for all miRNAs

File Name: Supplementary Data 2

Description: Annotated compounds and RPM values for selected miRNAs

File Name: Supplementary Data 3

Description: Annotated compounds and expression level for selected miRNAs after adjusting batch effect with ComBat

File Name: Supplementary Data 4

Description: miRNAs relevant to neurological diseases

File Name: Supplementary Data 5

Description: Validation data for 44 selected compounds

File Name: Supplementary Data 6

Description: EC50 and max fold changes values for selected compounds in primary rat neurons and human NGN2-iNs

File Name: Supplementary Data 7

Description: List of DEGs in human iPSC-neurons after 72h of treatment with digoxin, oleandrin, proscillaridin A and their predicted probabilities as miR-132 targets. N= 3 vs 3 for each cardiac glycoside. Cut-off threshold: $|FC| > 2$ and adjusted $p < 0.05$. Wald test with FDR correction analyzed using DESeq2.

File Name: Supplementary Data 8

Description: Overview of published studies on effects of cardiac glycosides in animal models

File Name: Supplementary Data 9

Description: List of commercial miRNA primers used for miRNA RT-qPCR

File Name: Supplementary Data 10

Description: List of mRNA primer sequences used for mRNA RT-qPCR

File Name: Supplementary Data 11

Description: List of other key resources used in this study